Background
(1) Department of Health Management, New York Medical College, Valhalla, New York, USA (2) University of British Columbia, Vancouver, British Columbia, Canada (3) Misdiagnosis Association, Seattle, Washington, USA KeywordsPsoralen…
(1) Department of Health Management, New York Medical College, Valhalla, New York, USA (2) University of British Columbia, Vancouver, British Columbia, Canada (3) Misdiagnosis Association, Seattle, Washington, USA KeywordsPsoralen…
(1) Department of Health Management, New York Medical College, Valhalla, New York, USA (2) University of British Columbia, Vancouver, British Columbia, Canada (3) Misdiagnosis Association, Seattle, Washington, USA KeywordsMycosis…
(1) Department of Health Management, New York Medical College, Valhalla, New York, USA (2) University of British Columbia, Vancouver, British Columbia, Canada (3) Misdiagnosis Association, Seattle, Washington, USA KeywordsClinical…
(1) Department of Health Management, New York Medical College, Valhalla, New York, USA (2) University of British Columbia, Vancouver, British Columbia, Canada (3) Misdiagnosis Association, Seattle, Washington, USA KeywordsEpidemiologyAgeEthnicitySexIncomeEducation…
(1) Department of Health Management, New York Medical College, Valhalla, New York, USA (2) University of British Columbia, Vancouver, British Columbia, Canada (3) Misdiagnosis Association, Seattle, Washington, USA KeywordsSézary…
(25.1) where C is the drug concentration at depth x, D represents the diffusion coefficient in the membrane, and t is the time. Initially, the membrane is free of drug:…
(1) Department of Pharmaceutics and Drug Delivery, The University of Mississippi, Oxford, MS 38677, USA (2) Institute for Drug Delivery and Biomedical Research, Bangalore, India Muralikrishnan Angamuthu Email: Krisamurali@gmail.com KeywordsSkin…
Fig. 9.1 The electrochemical transdermal device (ECTD). (a) Schematic cross section through the electrochemical patch. A external voltage source, B hydrogel, C spacer, D backing foil, E adhesive layers, F…
(22.1) Viable skin (22.2)where C is the drug concentration, D is the diffusion coefficient, h is the thickness of the stratum corneum, H is the thickness of the skin, t…
Fig. 18.1 Approaches aiming at facilitation of peptide/protein transport across the skin This chapter will focus on the use of microneedle (MN) arrays as medical devices to disrupt the barrier…